Talis Biomedical Corp expected to post a loss of 91 cents a share - Earnings Preview

Talis Biomedical

07/08/2021 02:48

* Talis Biomedical Corp  TLIS.OQ   TLIS.O  is expected to report
results on August 10.
​* Refinitiv's mean analyst estimate for Talis Biomedical Corp
is for a loss of 91 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Talis
Biomedical Corp is $13​, about 23.7% above​ its last closing
price of $9.92. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.75       -0.75      -4.61     Missed  -514.7
 Dec. 31 2020  -0.78       -0.78      -20.84    Missed  -2,554
                                                        .8
                                                        ​
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated August 7 at 01:48 GMT.  All
figures in US dollars unless otherwise stated